Results 131 to 140 of about 1,364 (160)

Droxidopa or Atomoxetine for Refractory Hypotension in Critically Ill Cardiothoracic Surgery Patients.

Journal of Cardiothoracic and Vascular Anesthesia, 2023
OBJECTIVE To evaluate the effects of droxidopa or atomoxetine on intravenous (IV) vasoactive agent discontinuation in cardiothoracic intensive care unit (ICU) patients with hypotension refractory to midodrine. DESIGN Single-center, retrospective cohort
Julia Lessing, Shawn J. Kram, Jerrold H. Levy, L. Grecu, Jason N. Katz   +4 more
semanticscholar   +1 more source

Oral Vasoactive Medications: A Summary of Midodrine and Droxidopa as Applied to Orthostatic Dysfunction

Cardiology: Open Access, 2022
This is a summary of the uses and applications of two vasoactive drugs, Midodrine (ProAmatine) and Droxidopa (Northera), in the treatment of Orthostatic Dysfunction (OD) disorders, including Neurogenic Orthostatic Hypotension, Postural Orthostatic ...

semanticscholar   +1 more source

Droxidopa in the Management of Hepatorenal Syndrome

Journal of pharmacy and practice, 2022
Purpose Hepatorenal syndrome (HRS) is renal dysfunction associated with the hemodynamic consequences of advanced liver disease and cirrhosis. HRS is associated with a high mortality, and there remain high failure rates with first-line therapy aimed at ...
Andrea Bejjani, Youqi Zhang, Allison Behrens, B. Murray, N. Shah   +4 more
semanticscholar   +1 more source

Successful Treatment of Refractory Orthostatic Intolerance (OI) With Droxidopa

La Clinica pediatrica, 2022
Orthostatic intolerance (OI) is a disorder of the autonomic nervous system characterized by the provocation of symptoms with standing and the improvement in symptoms with recumbency.1 In adults, postural orthostatic tachycardia syndrome (POTS), a form of
Christina Kokorelis, J. Bodurtha, Kelsey S Guthrie, Peter C. Rowe   +3 more
semanticscholar   +1 more source

Abstract 4145249: THE TWO-HIT HYPOTHESIS?: NEW ONEST SEVERE CARDIOMYOPATHY AND CARDIAC ARRYTHMIA IN A HIGH RISK PATIENT WITH NEUROGENIC ORTHOSTATIC HYPOTENSION ON DROXIDOPA

Circulation
Introduction: Droxidopa (DD) is the second FDA approved drug after midodrine for neurogenic orthostatic hypotension (nOH). Isaacon et al reported that 19 (5.4%) of total 350 patients on droxidopa had 25 cardiac events, most commonly atrial ...
Y. N. Htay, Varun Victor, Lakshmi Murugesan, Thi Ri, Dilanthy R. Annappah, Billal Sikandar, Ataul Qureshi, Ryan Koene   +7 more
semanticscholar   +1 more source

Droxidopa for Vasopressor Weaning in Critically Ill Patients with Persistent Hypotension: A Multicenter, Retrospective, Single-Arm Observational Study

Journal of Intensive Care Medicine
Background Persistent vasopressor requirements are a common reason for delayed liberation from the intensive care unit (ICU) and adjunct oral agents are sometimes used to hasten time to vasopressor discontinuation.
Andrew J. Webb, Gianna Lh Casal, Kelly A. Newman, Justin R Culshaw, Kalynn A. Northam, Edmond Solomon, Sarah M Beargie, Riley Johnson, Natasha D Lopez, Bryan D Hayes, Russel J Roberts   +10 more
semanticscholar   +1 more source

Method Development and Validation of Droxidopa by RP-UPLC

, 2021
A simple, rapid, accurate and economical method has been developed for the quantification of droxidopa by UPLC. The chromatographic system was equipped with Phenomenex column C18 (50mm x 3.0mm, 3µ) as stationary phase and UV detector at 235nm, in ...
Bharani Pandilla, K. Chitra, C. Nalini, P. Ashok   +3 more
semanticscholar   +1 more source

A quality by design (QbD) strategy for developing and validating Droxidopa in API and formulation using an RP-HPLC procedure ensuring regulatory compliance

Analytical Chemistry Letters
Background: Droxidopa, a prodrug for neurogenic orthostatic hypotension, requires precise quality analysis. RP-HPLC is valued for its sensitivity and reliability in pharmaceutical quality control, but traditional methods are time-consuming and lack ...
Sandhya Madhuri Maddala, Ravi Parimi, Pravallika K Elvina   +2 more
semanticscholar   +1 more source

Exploration and evaluation of adverse event signals of droxidopa based on the FAERS database.

Expert Opinion on Drug Safety
BACKGROUND This study aims to utilize the FDA's Adverse Event Reporting System (FAERS) for data analysis to explore the potential adverse events associated with Droxidopa in real-world settings, thereby providing reference information for clinical ...
Xinnan Chen, Haohao Zhu, Ying Jiang, Man Tian   +3 more
semanticscholar   +1 more source